SYP and Cognitive impairment: VX-765 treatment of aged J20 significantly reversed cognitive impairment, decreased synaptophysin immunoreactivity, and decreased dendritic spine density without increased altering pro-inflammatory cytokine levels, GFAP+-astrocytes and Iba1+-microglia numbers.